FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT ATTORNEY DOCKET NO.: SERIAL NO.: 10/066,964	
APPLICANT: BIGGADIKE, et. al.	
FILING DATE: GROUP	
02/04/2002 1616	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
U.S. PATENT DOCUMENTS	
THAT	Filing Date If Appropriate
Initiale Patent Issue Date Name Class Subclass	11 Appropriate
Number	
BB A1 3,067,197 12/04/62 Agnello et al.	
A2 3,639,434 02/01/72 Oxley et al. ———————————————————————————————————	
A3 3,828,080 08/06/74 May et al.	
A4 3,856,828 12/24/74 Phillips et al.	
A5 3,981,894 09/21/76 Phillips et al.	
A6 3,989,686 11/02/76 Phillips et al.	
A7 4,093,721 06/06/78 Phillips et al.	
A8 4,187,301 02/05/80 Edwards	
A9 4,188,385 02/12/80 Edwards —	
A10 4,198,403 04/15/80 Alvarez	
A11 4,261,984 04/14/81 Alvarez	
A12 4,263,289 04/21/81 Edwards —	
A13 4,267,173 05/12/81 Draper ——	
A14 4,285,937 08/25/81 Kalvoda —	
A15 4,310,466 01/12/82 Edwards —	
A16 4,377,575 03/22/83 Phillips et al.	
A17 4,607,028 08/19/86 Schmidlin	
A18 4,710,495 12/01/87 Bodor —	
A19 4,861,765 08/29/89 Jouveinal ——————	
A20 4,992,474 02/12/91 Skidmore et al	
A21 4,994,439 02/19/91 Longnecker et al.	
A22 4,996,335 02/26/91 Bodor —	
A23 5,250,293 10/24/86 Gleich	-
A24 5,420,120 05/30/95 Boltralik —————	
A25 5,707,984 01/13/98 Tjoeng et al.	
A26 5,849,265 12/98 Li-Bovet et al.	
A27 5,919,776 11/13/02 Hagmann et al.	
A28 5,972,920 10/26/99 Seidel —	
A29 5,981,517 11/09/99 Bodor	
A30 6,395,300 05/02 Straub, et al.	
Continued on page	<u> </u>
FOREIGN PATENT DOCUMENTS	
Document Publication	Translation
Number Date Country Class Subclass	Yes No
Trainer Country Class Subtrass	-
Continued on page	
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	<u>.</u>
Continued on page	
EXAMINER Padio DATE CONSIDERED 12/17/03	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through in conformance and not considered. Include copy of this form with next communication to the applicant.	h citation if not

FORM PTO-1449 INFOBERATION SISCLOSURE STATEMENT					ATTORNEY DOCKET NO.: SERIAL NO: 10/066,964					
/			Je and			APPLICANT: BIG	GADIKE, et. al.			
- 1	. MAY	0 2003	13			FILING DATE:		GROUP		
1.		- 6564	1			02/04/2002				
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	E.		Æ/					1616		
	CG TA	ADFMAR!	7	U.S. PAT	ENT D	OCUMENTS				
									Filing Date If Appropriate	
LX8	miner itials		Patent	Issue Date		Name	Class	Subclass	II reppropriate	
1111	ILIAIS		Number							
								<u> </u>		
					ntinued					
					ATENT	DOCUMENTS			Translation	
			Document	Publication Date		Country	Class	Subclass	Yes No	
	1	-	Number		PCT	Country	Class	Subclass	-	
- 12	3	B1	92/14472	09/03/92 11/30/95	PCT				 	
	ļ	B2	95/31964		PCT		_			
		B3	96/19199	06/27/96	PCT					
	<u> </u>	B4	97/05136	02/13/97	PCT					
		B5	97/15298	05/01/97	PCT				 	
		B6	97/24365	07/10/97	PCT			 	 	
		B7	97/46243	12/11/97	PCT				 	
		B8	98/43630	10/08/98	PCT				 	
\vdash		B9	99/01467	01/14/99 05/27/99	PCT				-	
		B10	99/25359	05/27/99	PCT				 	
		B11	99/32089	07/06/00	PCT				 	
\vdash		B12	00/38811	08/15/00	PCT				 	
 -		B13	00/57401	01/18/01	PCT				 	
┝╼┼		B14	01/04118	03/08/01	PCT					
\vdash		B15 B16	01/15744 01/20331	03/08/01	PCT					
├		B17	01/62722	08/30/01	PCT				-	
\vdash	· · · · · · · · · · · · · · · · · · ·	B18	01/78736	10/25/01	PCT					
\vdash		B19	01/78739	10/25/01	PCT					
┝╼┼		B20	01/78741	10/25/01	PCT					
\vdash		B21	01/78745	10/25/01	PCT					
\vdash		B22	02/00199	01/03/02	PCT		-			
┝		B23	02/00679	01/03/02	PCT					
		B24	02/007767	01/31/02	PCT					
		B25	02/008243	01/31/02	PC1					
		B26	02/013868	02/21/02	PCT					
		B27	02/26723	04/04/02	PCT					
		B28	02/053186	07/11/02	PC1	•				
		B29	02/066422	08/29/02	PC1					
		B30	02/070490	09/12/02	PC1					
135	B	B31	02/076933	10/03/02	PC1			<u> </u>		
	Continued on page 3									
	OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
				Co	ntinued	on page	DATEC	ONŞIDERED		
EXA	AMINE	200	lio				1/2/1	7/03		
EXA	MINE	R: Initia	if citation conside	ered, whether or not cita	ation is i	n conformance with	MPEP § 609; D	ráw line through	citation if not	
in co	in conformance and not considered. Include copy of this form with next communication to the applicant.									

FORM PTO)-1449 P103 D	ISCLOSURE STA	ATEMENT	ATTORNEY DOCKET NO.: SERIAL NO: 10/066,964					
/ /		· %			APPLICANT: BIGG	ADIKE, et. al			
1 / 1100	1 0 20	i k			FILING DATE: GROUP				
(, · NO)	•				02/04/2002		1616		
12					<u> </u>				
(A)	PADE	84.0	U.S. PAT	ENT D	OCUMENTS				
F	HADE							Filing Date If Appropriate	
Examiner Initials			Issue Date	- 1	Name	Class	Subclass		
		Number							
								<u></u>	
				ntinued					
			FOREIGN F	ATEN	T DOCUMENTS				
		Document	Publication					Translation Yes No	
		Number	Date		Country	Class	Subclass		
133	B31	02/085296	10/31/02	PCT					
	B32	02/088167	11/07/02	PCT					
	B33	02/100879	12/19/02	PCT					
	B34	03/013427	02/20/03	PCT					
	B35	03/033000	04/24/03	PCT					
	B36	03/035668	05/01/03	PCT					
	B37	03/040691	05/15/03	PCT					
	B38	03/042229	05/22/03	PCT					
	B39	03/042230	05/22/03	PCT					
	B40	0004773	10/17/79	EP					
	B41	0057401	08/11/82	EP				\	
	B42	0135476	03/27/85	EP				YES US4607028	
	B43	0179583	04/30/86	EP				1 001007020	
	B44	0416951	03/13/91	EP	***				
- 	B45	0418716	03/27/91	EP.				YES	
		0110110					7	WO9104252	
	B46	0521455	01/07/93	EP					
	B47	0640616	03/01/95	EP				YES US5608093	
	D40	0040500	04/05/05	EP			_	ABSTRACT	
 	B48	0646593 2336693	04/05/95 02/06/75	DE				NO	
<u> </u>	B49 B50	2538569	03/03/77	DE				NO	
 	B51	1384372	02/19/75	GB				1.0	
	B52	1438940	06/09/76	GB				 	
- 	B53	1517278	07/12/78	GB					
	B54	2079755	01/27/82	GB				+	
 	B55	2140800	12/05/84	GB				 	
	B56	04208267	07/29/92	JP				ABSTRACT	
	B57	580494	10/24/86	FR				YES US4948583	
	B58	109656	02/22/98						
PAB	B59	872389	04/02/87	ZA					
	Continued on page								
		OTHER DOC	UMENTS (Including	Author,	Title, Journal-Date,	Page Numbe	r, Etc.)		
			Co	ntinued	on page				
EXAMINER Padio DATE CONSIDERED 12/17/63									
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									

### 1 2003 TO/086,964 ##PLICANT BIGGADIKE, et.al. FILING DATE: ### 1 2003 TO/086,964 ##PLICANT BIGGADIKE, et.al. FILING DATE: ### 1 2004 TO/086,964 ### 1 2004 TO/086,964 ### 2 2004/2002 1616 ### 1 2004/2002 1616 ### 2 2004/2	FORM PTO		TSCLOSURE STA	ГЕМЕПТ	ATTORNEY DOCKET NO.: PG4709		SERIAL NO: 10/066,964				
FILING DATE: 20/20/20/202 1516 Patent		24.15	Elonin								
U.S. PATENT DOCUMENTS Patent Issue Date Name Class Subclass Pring Date Number Subclass Pring Date Number Subclass Pring Date Number Number Document Patent Issue Date Number Document Patent Pa	/:	,	18								
U.S. PATENT DOCUMENTS Patent Issue Date Name Class Subclass Fings Date: Continued on page FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Vu New York Patent Number Date Country Class Subclass Vu New York Patent Number Date Country Class Subclass Vu New York Patent Number Date Country Class Subclass Vu New York Patent	/	w 4 ft '	E mo								
Patent Number Patent Number Name Class Subclass Finigible Mapproprise M	100	NA LO									
Number Continued on page	12		E/	U.S. PATENT	DOCUMENTS						
Number Continued on page	1	d man	ART								
Document Potelization Country Class Subclass Translation Ver No.	Examiner Initials	MADE	Patent Number	Issue Date	Name	Class	Subclass	If Appropriate			
Document Politication Politi											
Document Politication Politi						 					
Document Number Dots Country Class Subclass Translation Vest No.		L		Continue	ed on page			-			
Number Date Country Class Subclass Ver No				FOREIGN PATE	NT DOCUMENTS						
Number Date Country Class Subclass Continued on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) BD C1 Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornear Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1798. C3 R. Woodford et al., "Activity and bloavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'i Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17/6-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 a-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Blochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Clycol Solutions of Noninoine Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., "Inirinsic Potencies of Novel Thiol Ester Corticosteroids R5-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1682-1685 C8 Isogai, Mitsutaka, et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Algibrino et al., "Automated Radiosynthesis of No-carrier-added [S-fluoremethyl-18F]Fluticasone Proplonate as a Radioracer for Lung Deposition Studies with PET" Journal of Labelled C			Document	Publication							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Der C1 Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 ca-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactanis", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Plucionnoide" Arch Dermatol, V125, December 1989, pp. 1682-1685 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metiabolities for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Red Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Frankin I. Algibrition et al., "Automated Ra			Number	Date	Country	Class	Subclass	18 1 140			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Der C1 Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 ca-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactanis", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Plucionnoide" Arch Dermatol, V125, December 1989, pp. 1682-1685 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metiabolities for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Red Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Frankin I. Algibrition et al., "Automated Ra											
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Delta Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and biosvaliability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 ca-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Intinsic Potencies of Novel Thiol Ester Corticosteroids Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids Re-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Plucionnoids" Arch Dermatol, V125, December 1989, pp. 1682-1685 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolities for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Radio Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Frankin I. Algibiritio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluiticasone Propionate as a						ļ					
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Delta Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and biosvaliability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 ca-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Intinsic Potencies of Novel Thiol Ester Corticosteroids Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids Re-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Plucionnoids" Arch Dermatol, V125, December 1989, pp. 1682-1685 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolities for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Radio Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Frankin I. Algibiritio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluiticasone Propionate as a		<u> </u>				J		<u> </u>			
C1 Janette M. Mahoney et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 179-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 -Acylates" J. Org. Chemp., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 - 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonlonic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 Sogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticold Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1983, 141-145. C9 S. J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Algbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethy/-18F							74				
the rat cornea" Current Eye Research, Vol. 4, No. 5, 1985, pp. 531-535 C2 Richard A. Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 cr-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Miceliar Solubilization of Timobesone Acetate in Aquecus and Aquecus Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Ajbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18]-Flutticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceutical and Bi		1						4			
C2 Richard A, Kenley et al., "An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (9810), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J, Kerteaz et al., "Thiol Esters from Steroid 178-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical conticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonlonic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolities for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Algibriho et al., "Automated Radiosynthesis of No-carrier-added (S-fluoromethyl-19FjFiuticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Dramacerisiati	BB	C1					silver nitrate cau	iterization of			
Materials in Both Cream and Ointment Formulations," Drug Development and Industrial Pharmacy, Vol. 11 (98:10), 1985, pp. 1781-1796. C3 R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1989) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 178-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 -Acylates' J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonlonic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids R5-85095 and R5-21314 as Compared With Call Chetarol 17-Propionate and Fluocinonide' Arch Dermatol, Vol. 125, December 1989, pp. 1682-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added (S-fluoromethyr-18FjFuticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceutical No. 1, 1997, pp. 589-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-M	1		the rat cornea CL	irrent Eye Research, vol.	4, NO. 5, 1965, pp. 551-54	othed for A	nalyzina Active	and Eveinient			
compared with Lidex and Dermovate creams and ointments and Betnovate cream" Int'l Journal of Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolities for the Glucocorticoid Receptor of Rat Skin Tissus" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Algbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Filuticasone Proplonate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-MMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 18, 1997, pp. 569-705 C12 Nisha Mistry et al., "Characterisation of impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol.		62	Materials in Both (9&10), 1985, pp.	Cream and Ointment Forr 1781-1796.	mulations," Drug Developm	nent and In	dustrial Pharma	cy, Vol. 11			
Pharmaceutics, Vol. 26 (1985) pp. 145-155 C4 Denis J. Kertesz et al., "Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α-Acylates" J. Org. Chem., Vol. 51, 1986, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1682-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Filuticasone Proplonate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 18, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysi		C3	R. Woodford et al	R. Woodford et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment							
Participation by 17 a-Acylates" J. Org. Chem., Vol. 51, 1886, pp. 2315-2328. C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluorometrly/-18F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw			Pharmaceutics, V	ol. 26 (1985) pp. 145-155							
C5 Popper, T.L., et al., "Structure-Activity Relationship of a series of novel topical corticosteroids", Journal of Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-738 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-19F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., "Inpurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 C14 R.C. Garner et al., "A validation study companing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical an		C4					late Activation	and Internal			
Steroid Biochemistry 1987, 837 – 843 C6 John T. H. Ong et al., "Micellar Solubilization of Timobesone Acetate in Aqueous and Aqueous Propylene Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethy/-18F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-MMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 597-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whethe			Participation by 1	7 α-Acylates" J. Org. Che	m., Vol. 51, 1986, pp. 231	5-2328.					
Glycol Solutions of Nonionic Surfactants", Pharmaceutical Research, Vol. 5, No. 11, 1988, pp. 704-708 C7 John T. H. Ong et al., Intrinsic Potencies of Novel Thiol Ester Corticosteroids RS-85095 and RS-21314 as Compared With Clobetasol 17-Propionate and Fluocinonide" Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Fuluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18-F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not			Steroid Biochemis	stry 1987, 837 – 843							
Compared With Clobetasol 17-Propionate and Fluocinonide* Arch Dermatol, Vol. 125, December 1989, pp. 1662-1665 C8 Isogai, Mitsutaka, et al., "Binding affinities of Mometasone Furoate and related compounds including its Metabolites for the Gluococrticoid Receptor of Rat Skin Tissue* J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator Ms and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Blomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not		C6	Glycol Solutions	of Nonionic Surfactants", F	Pharmaceutical Research,	Vol. 5, No.	11, 1988, pp. 7	04-708			
Metabolites for the Glucocorticoid Receptor of Rat Skin Tissue" J. Steroid Biochem. Mol. Biol. 1993, 141-145. C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluticasone Proplonate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 DATE CONSIDERED DATE CONSIDERED C14 DATE CONSIDERED C25 DATE CONSIDERED DATE CONSIDERED DATE CONSIDERED C27 DATE CONSIDERED		C7	Compared With C 1662-1665	lobetasol 17-Propionate a	and Fluocinonide" Arch De	ermatol, Vo	. 125, Decembe	r 1989, pp.			
C9 S.J. Lane et al., "Evaluation of a New Capillary Electrochromatography/Mass Spectrometry Interface Using Short Columns and High Field Strengths for Rapid and Efficient Analyses," Rapid Communications in Mass Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Blomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 DATE CONSIDERED C14 C15 C2 C2 C2 C2 C2 C2 C2 C		C8									
Spectrometry, Vol. 10, 1996, pp. 733-736 C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not		C9									
C10 Franklin I. Aigbirhio et al., "Automated Radiosynthesis of No-carrier-added [S-fluoromethyl-18F]Fluticasone Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Gamer et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not			Short Columns ar	d High Field Strengths fo	r Rapid and Efficient Anal	yses," Rapi	d Communication	ons in Mass			
Propionate as a Radiotracer for Lung Deposition Studies with PET" Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not			Spectrometry, Vo	l. 10, 1996, pp. 733-736			49				
Radiopharmaceuticals, Vol. 39, No. 7, 1997, pp. 569-584 C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not	1 1	C10									
C11 Nisha Mistry et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not						oumai oi Li	abelled Compou	inus anu			
directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis Vol. 16, 1997, pp. 697-705 C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not		C11				es of flutica	sone propionate	usina			
C12 Nisha Mistry et al., Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not			directly coupled I-	IPLC-NMR spectroscopy							
distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, Vol. 19, 1999, pp. 511-517 C13 N. Smith et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 C14 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER DATE CONSIDERED L2 L3 L3 DATE CONSIDERED L2 L3 L3 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not		C12	Nisha Mistry et al	Impurity profiling in bulk	pharmaceutical batches i	usina 19F N	IMR spectrosco	ov and			
capillary electrochromatography," Journal of Chromatography A., Vol. 832, 1999, pp. 44-54 R.C. Garner et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴ C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER DATE CONSIDERED 12 13 0 5 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not			distinction between Pharmaceutical a	en monomeric and dimeric nd Biomedical Analysis, \	impurities by NMR-based /ol. 19, 199 <mark>9, pp. 511-517</mark>	diffusion r	neasurements,"	Journal of			
of 14C-labelled drugs in plasma, urine and faecal extracts", Journal of Pharmaceutical and Biomedical Analysis Vol. 24, 2000, pp. 197-209 Continued on page 5 EXAMINER DATE CONSIDERED 12/9/03 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not		C13						es used in			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not	72	C14									
EXAMINER DATE CONSIDERED 12/14/03 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not	120		Analysis Vol. 24,								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not			7	Continue	d on page 5	T =					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not	EXAMINER		radio								
	EVANDED	· Tarie!-	if gitneing	d substhance and altertion	in in conformation with a co			aitation if not			
							naw line through	onanon n not			

	FORM PTO-1449 INFORMATION EISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4709		SERIAL NO:		
INFORMA	ON	DS COSURE STA	I ENIEN I	PG4709 10/066,964					
/		(e)			ANT: BIGGA	DIKE, et. al.			
.	MOV 1 (2003 だ			FILING DATE: GROUP				
13		[5]		02/04/20	002		1616		
- K	Te THAI	- URI	U.S. PATENT	DOCUMEN	TS				
	THE REAL PROPERTY.	DE MAN					T	Filing Date	
Examiner Initials		Patent	Issue Date	Nan	ne	Class	Subclass	If Appropriate	
		Number			g <u>. </u>				
						 		 	
				d on page	renime.				
		T 200	FOREIGN PATE	NT DOCUM	ENIS			Translation	
		Document Number	Publication Date	Coun	itru	Class	Subclass	Yes No	
	 	Number		Jour	ici y	Ciuss	Bubelass		
								1	
		OTHER DOCK	Continue MENTS (Including Author	d on page	mal Data De	oo Numbar	F4a)		
	C15		et al. "Fluticasone propior					asthma	
2-20	"	control than low-d	ose inhaled corticosteroid						
95	1	December 2000, I		1			11 (1 145)		
	C16		n et al., "Comparison of S lild-to-Moderate Asthma" (Budesonide	
	C17		et al., Re-evaluation of the					et al. 1989)	
·		and description of	two new clusters in the h	ominis group	based on 16				
	040	Systematic & Evo	lutionary Microbiology (20	01) Vol. 51, p	op. 633-643				
	C18		al., "Association of specifilation of Boston women",						
	C19		ng-Williamson et al., "Inha						
			onary Disease," Am. J. Re						
	C20		et al., "Solubilization by ca armaceutics Vol. 245, 200			eful constan	its for the log-lir	near model,"	
	C21	C. Baumgarten et	al., "Initial Treatment of S	ymptomatic f	Mild to Mode				
	}		sone Propionate (50/250)	ıg) Combinat	tion Product ((SAS 40023)" European Jo	umal of	
	C22		2002, Vol. 7, pp. 1-7 ret al., "Step-down therap	v with low-do	se fluticason	a-calmeter	l combination o	or medium-	
	022		ilkane 134a-beclomethaso						
		pp. 929-935							
	C23		er et al., "Impact of Inhale e Health-Related Quality o						
		2002. pp. 435-440		I Life of Paul	ents with Ast	nina, Am. c	i. Respir. Meg.,	voi. 1, 140. 0,	
	C24	William Busse et a	al., "Steroid-sparing effect						
			e daily in a single product					opionate 250	
	C25		wice daily" J. Allergy Clin. SYNTHESIS AND EVALU					SERIES OF	
			ID 17. ALPHA -ESTERS						
		MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, Vol. 34, No. 8, August 1991, pp. 2468-2473							
	C26	PETER J BARNES, "Novel approaches and targets for treatment of Chronic Obstructive Pulmonary Disease" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 160, 1999, pp. S72-S79							
	C27		Combination Therapy", Pl						
		Vol.11, No. 5/6, 19	998, pp. 397 – 399						
ا ا	C28		S, "Chronic Obstructive Pr						
PB		415 – 423	RMACOLOGICAL SCIENC	JEO, ELOEVI	ENIK IKENL	A JOURINA	rr' AOI' 19' 140'.	io, iaao, pp.	
			Continued	on page 6					
EXAMINER		Pod	(a)			DATEGO	NSIDERED		
EXAMINED	· Initial	lif citation considere	d, whether or not citation is	in conforma	nce with MDI	1 /// (77 0	citation if not	
			u, whether of not chanon is				aw mie mongu	James of Hot	

FORM PTO	FORM PTO-1449				ATTORNEY DOCKET NO.: SERIAL NO:				
INFORMATION PIST OSURE STATEMENT					PG4709 10/066,964				
	0''	6.7							
/	•	61			APPLICANT: BIGGADIKE, et. al.				
[.]	18V 1 0	2003 克			FILING DATE:	•	GROUP		
1-0		*			02/04/2002		1616		
	& TRAC	CAN PROPERTY.	U.S. PATEN	NT DC	DCUMENTS				
¥7	100					1		Filing Date If Appropriate	
Examiner Initials		Patent	Issue Date		Name	Class	Subclass	11 reppropriate	
		Number							
· · · · · · · · · · · · · · · · · · ·		<u> </u>	Contin	nued o	n page				
			FOREIGN PAT	TENT	DOCUMENTS		·		
	Γ	Document	Publication					Translation	
		Number	Date		Country	Class	Subclass	Yes No	
								 	
					<u> </u>				
				·		1		 	
		<u> </u>	Contin	nued o	n page			<u></u>	
		OTHER DOCU	MENTS (Including Au			age Numbe	r. Etc.)		
	C29		"Long acting beta agor					12 1998 nn	
7373	023	1114-1118	Long being beta ager	111313 ,	, AOOH MILIANT ANI	21111010	, , , , , , , , , , , , , , , , , , ,	12, 1330, pp.	
17/	C30		RETAL, "Dual compon	ents c	of optimal asthma ther	apv: scienti	fic and clinical ra	tionale for	
/			ting beta-agonists with						
			SSOCIATION, Vol 101						
	C31	T VAN DER MOL	EN ET AL, "EFFECTS (OF TH	IE LONG ACTING BE	TA AGONIS	T FORMOTER	OL ON	
·		ASTHMA CONTR	OL IN ASTHMATIC PA	TIEN"	TS USING INHALED	CORTICOS	TEROIDS", Vol.	52, No. 6,	
		1997, pp. 535-539)						
	C32		I, "A Novel Class of po						
		Halogeno Substitu	ted Corticosteroids", A	rzene	imittel Forschung, Vo	l. 29, No. 11	<u>, Nov. 1979, pp.</u>	1662-1667	
	C33		S, "Efficacy of Inhaled		costeroids in Asthma",	The Journa	of Allergy and	Clinical	
			102, No. 4, pp. 531-53		107/00				
	C34		o. 2002/0081266 publ. (
	C35		o. 2002/0103392 publ. (
	C36		o. 2002/0165211 publ. o				<u></u>		
, ,	C37		o. 2002/0173496 publ. o						
	C38		o. 2002/0177581 publ. o						
	C39		o. 2003/0073676 publ. o						
	C40		o. 2003/0109511 publ. o						
	C41		o. 2003/0144257 publ. o						
33	C42	US Publication No	o. 2003/0158163 publ. o	on 08/	21/03				
			Conti	nued o	n page				
EXAMINER	٢	D- 1.	-			DATE, C	ONSIDERED		
		Dadio				12/1	7/03		
			d, whether or not citatio				raw line through	citation if not	
i :		Imal.	.da aans, af thia fama sui	th mar	t communication to the	!:			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. SERIAL NO. 10/066,964					
)·\ m	E.]			APPLICANT					
/ /	•	6			BIGGADIKE, Keith					
(. 🖽	N 9 0 8	100 N			FILING DATE		GROUP			
12.					04 Feb 2002 ·	·				
	b .	CALCIA	U.S. I	ATENT D	OCUMENTS					
Examiner Initials	TRADE	Patent	Issue Date		Name	Class	Subclass	Filing Date If Appropriate		
	-	Number	ļ	ļ <u> </u>			ــــــــــــــــــــــــــــــــــــــ			
	 		<u> </u>							
	ļ			 				2		
	 			<u> </u>				7		
<u> </u>	 		 	<u> </u>			- 5	1801		
	 	<u> </u>	 	 			 	0 0		
 	 			 			<u> </u>	201		
	 		 	 				80 3		
	 		 	ļ				0 8		
	1			 				2		
	<u> </u>	L	<u> </u>	<u> </u>				3		
										
		ı · · · · · · · · · · · · · · · · · · ·	Τ	T		`		Translation		
	1]				Class	Subclass	Yes No		
	 		 	 			Dubtiass .			
	 			 				 		
				1				 		
				 -			 	 		
	<u> </u>			 			 	 		
			·	t						
	1		 					 		
					****		1			
•										
	•		C	ontinue on p	age					
		OTHER DOCUM	MENTS (Includi	ng Author,	Title, Journal-Date,	Page Numb	er, Etc.)			
_	CB	Knobil, K., et. al	, "ADDING SAI	METEROL	IS MORE EFFECTI	VE THAN I	NCREASING T	HE DOSE		
5	l	OF FLUTICASC	NE FOR PATIE	nts with	ASTHMA WHO AR	E SYMPTO	MATIC ON LO	W DOSE		
35B	i	FLUTICASONE	," European Resp	piratory Rev	iew, Copenhagen, DK	L, vol 12, no.	SUPPL 29, Dec	ember 1998		
	CC	(1998-12), pages	198-208, XP000	1992769	omena on donara					
~~		SERIES " Journa	al., 1/ HETEK	DAKOTE E	STERS OF CORTICO merican Chemical Soc	OSTEROIDS	5 Z. 11-BEJA H	TYDROXY		
BB]	1987, pages 1581	1-1588 XP00215	1810	nerican Cuentical 200	nety, washii	igion, OS, voi. 3	50, 110. 9,		
		T Booton	. 1000,1400213							
				· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·	 		
	<u> </u>		·							

							··			
										
			· · · · · · · · · · · · · · · · · · ·							
				· · · · · · · · · · · · · · · · · · ·						
				Continue on	page					
EXAMINER		toad	eo.			DATEC	ONSIDERED	3		
EXAMINER	: Initia	l if citation consid	ered, whether or	not citation	is in conformance wit	h MPEP 8 6	19. Draw lind th	rough l		
citation if no	citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									